[{"id":"d849c811-e1a4-4e2a-879f-f191f73d4644","acronym":"TCD17197","url":"https://clinicaltrials.gov/study/NCT05086315","created_at":"2023-08-14T10:11:07.011Z","updated_at":"2024-07-02T16:35:00.248Z","phase":"Phase 1/2","brief_title":"First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","source_id_and_acronym":"NCT05086315 - TCD17197","lead_sponsor":"Sanofi","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bexatamig (IPH6101)"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 12/11/2025","primary_completion_date":" 12/11/2025","study_txt":" Completion: 11/11/2026","study_completion_date":" 11/11/2026","last_update_posted":"2024-05-29"}]